Alterity Therapeutics Ltd.

11/20/2026 | Press release | Distributed by Public on 11/20/2026 05:05

Letter of PricewaterhouseCoopers, dated November 20, 2026 (Form 6-K)

November 20, 2026

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Commissioners:

We have read the statements made by Alterity Therapeutics Limited (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Form 6-K concerning the change in its certifying accountant and provided in response to Item 16F(a) of Form 20-F of Alterity Therapeutics Limited dated November 20, 2026. We agree with the statements concerning our Firm contained therein.

Very truly yours

/s/ PricewaterhouseCoopers
Melbourne, Australia

Attachment

pwc.com.au

PricewaterhouseCoopers, ABN 52 780 433 757
2 Riverside Quay, SOUTHBANK VIC 3006,
GPO Box 1331 MELBOURNE VIC 3001
T: +61 3 8603 1000, F: +61 3 8603 1999, www.pwc.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

Alterity Therapeutics Ltd. published this content on November 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 20, 2026 at 11:05 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]